Clinical trial
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects…
NCT00077870 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00077870 |
|---|---|
| Title | A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis |
| Official title | A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | ocrelizumab |
| Enrollment | 237 |
| Start date | Feb 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Feb 16, 2004 |
| Last update posted | Sep 3, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: